- Datum15.01.2025
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Verrica Pharmaceuticals Inc. Aktie
Verkaufen
Kaufen
Verrica Pharmaceuticals Inc. Chart
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Verrica Pharmaceuticals Inc. Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
2,29 %
Intraday
-0,50 %
1 Woche
-45,31 %
1 Monat
-90,44 %
Seit Jahresbeginn
-90,44 %
1 Jahr
-92,65 %
3 Jahre
-95,43 %
5 Jahre
Wikifolio
Passender Service zu Verrica Pharmaceuticals Inc.
Webinar zu Verrica Pharmaceuticals Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)0,611-11,410
- Jahrestief / Hoch ($)0,611-11,410
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Verrica Pharmaceuticals Inc.
Keine Dividenden verfügbar
Termine von Verrica Pharmaceuticals Inc.
Keine aktuellen Termine
Beschreibung
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
